Pfizer's Q1 2025 earnings call painted a picture of gritty efficiency, disciplined R&D, and a pipeline trying to hit warp ...

Discover Pfizer's Q1 2025 earnings insights, including strategic R&D updates, financial guidance, and cost-saving initiatives.

Pfizer PFE reported first-quarter 2025 adjusted earnings per share of 92 cents, which comprehensively beat the Zacks ...

EPS estimates, maintains 2025 guidance, and targets $5.7 billion in cost savings through automation and R&D streamlining.

Biotech Biohaven has signed a non-dilutive funding deal with Oberland Capital as it awaits an FDA ruling on its ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The global Oral Proteins & Peptides Market , valued at US$7.35 billion in 2024, is forecasted to grow at a robust CAGR of 22.1%, reaching US$8.85 billion in 2025 and an impressive US$24.00 billion by ...

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ...

UNITED STATES – Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The ...

Get the next trade alert free. Pfizer Inc. PFE is discontinuing development of an oral glucagon-like peptide-1 (GLP-1) receptor agonist being investigated for chronic weight management.